Showing results (1631-1640 of 1,731) with videos related to

Sort By:
Pageof 174
Journal of Clinical and Translational Hepatology|May 23, 2024
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B PatientsJinlin Hou, Qin Ning, Zhongping Duan, et al.
Cell Death and Differentiation|April 29, 2020
Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidationPlamena R Angelova, Minee L Choi, Alexey V Berezhnov, et al.
Kardiologiia|November 29, 2011
[The study of hypotensive action of dinitrosyl-iron complex with glutathione containing drug oxacom in healthy volunteers]E I Chazov, O V Rodnenkov, A V Zorin, et al.
Cells|October 23, 2021
Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant DiseaseGonzalo P Solis, Tatyana V Kozhanova, Alexey Koval, et al.
Molecular Ecology|January 16, 2007
Mitogenetic structure of brown bears (Ursus arctos L.) in northeastern Europe and a new time frame for the formation of European brown bear lineagesUrmas Saarma, Simon Y W Ho, Oliver G Pybus, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2026
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis BEdward J Gane, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Msystems|May 7, 2026
Seasonal thawing of high Arctic soils triggers selective microbial growth and predationMargaret A Cramm, Ömer K Coskun, Francesco Montemagno, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2024
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 studyHarry L A Janssen, Young-Suk Lim, Pietro Lampertico, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
International Journal of Biological Macromolecules|February 12, 2020
S-layer protein 2 of Lactobacillus crispatus 2029, its structural and immunomodulatory characteristics and roles in protective potential of the whole bacteria against foodborne pathogensVyacheslav M Abramov, Igor V Kosarev, Tatiana V Priputnevich, et al.
Pageof 174